Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio
Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
hVIVO PLC reported annual revenue of £46.7 million, which met market expectations, prompting City brokers to evaluate whether the clinical research organisation has begun to reverse its fortunes after a
FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
Notice of Trading Update
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected